Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors
暂无分享,去创建一个
[1] Howard Lee,et al. Adherence and persistence rates of major antidiabetic medications: a review , 2022, Diabetology & Metabolic Syndrome.
[2] K. Boye,et al. Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review , 2022, Patient preference and adherence.
[3] E. Huang,et al. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.
[4] P. Sumithran,et al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation , 2021, The Lancet.
[5] I. Hirsch,et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.
[6] K. Boye,et al. Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data. , 2021, Journal of diabetes and its complications.
[7] W. Polonsky,et al. Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study , 2021, Diabetes Spectrum.
[8] A. Igarashi,et al. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment , 2020, Advances in Therapy.
[9] M. Hayter,et al. Fear of hypoglycemia in patients with type 1 and 2 diabetes: a systematic review. , 2020, Journal of clinical nursing.
[10] Xiao Ma,et al. The Unmet Medical Needs of Current Injectable Antidiabetic Therapies in China: Patient and Health Care Professional Perspectives. , 2020, Clinical therapeutics.
[11] K. Pecanac,et al. “Why Am I Not Taking Medications?” Barriers and Facilitators of Diabetes Medication Adherence Across Different Health Literacy Levels , 2020, Qualitative health research.
[12] A. Shaunik,et al. Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK , 2020, Diabetes Therapy.
[13] J. Stephenson,et al. Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States , 2020, Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy.
[14] A. Findley,et al. Development and First Use of the Patient’s Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit–Harm of Drugs Received During Clinical Studies , 2019, Drug Safety.
[15] A. Farmer,et al. Identifying routine clinical predictors of non‐adherence to second‐line therapies in type 2 diabetes: A retrospective cohort analysis in a large primary care database , 2019, Diabetes, obesity & metabolism.
[16] B. Frier,et al. Impact of severe hypoglycaemia on psychological outcomes in adults with Type 2 diabetes: a systematic review , 2019, Diabetic medicine : a journal of the British Diabetic Association.
[17] A. Mushlin,et al. Overcoming barriers to the use of metformin: patient and provider perspectives , 2019, Patient preference and adherence.
[18] T. Dehdari,et al. The determinants of anti-diabetic medication adherence based on the experiences of patients with type 2 diabetes , 2019, Archives of Public Health.
[19] K. Boye,et al. Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes , 2019, Patient preference and adherence.
[20] D. Cao,et al. Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sample. , 2019, Primary care diabetes.
[21] U. H. Panton,et al. The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States. , 2019, Journal of managed care & specialty pharmacy.
[22] B. Guerci,et al. Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes , 2019, Diabetes Therapy.
[23] Shigeru Tokita,et al. Factors associated with reluctance to initiate or continue oral antihyperglycemic agent (OAHA) treatments in type 2 diabetes mellitus patients in Japan: An observational patient-reported study. , 2019, Diabetes & metabolic syndrome.
[24] L. Husemoen,et al. A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes , 2019, Diabetes Therapy.
[25] N. Iyer,et al. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control. , 2019, Journal of managed care & specialty pharmacy.
[26] K. Khunti,et al. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia , 2019, Therapeutic advances in endocrinology and metabolism.
[27] Geltrude Mingrone,et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.
[28] F. Giorgino,et al. Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement , 2018, Patient preference and adherence.
[29] M. Kattan,et al. Clinical Inertia in Type 2 Diabetes Management: Evidence From a Large, Real-World Data Set , 2018, Diabetes Care.
[30] M. Horowitz,et al. Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management , 2018, Diabetes Care.
[31] A. Jarab,et al. A focus group study of patient’s perspective and experiences of type 2 diabetes and its management in Jordan , 2018, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[32] K. Khunti,et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review , 2017, Diabetes, obesity & metabolism.
[33] P. de Pablos-Velasco,et al. Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes , 2017, Diabetes Care.
[34] J. Piercy,et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes , 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.
[35] D. Cao,et al. Correlates of basal insulin persistence among insulin-naïve people with type 2 diabetes: results from a multinational survey , 2017, Current medical research and opinion.
[36] K. Boye,et al. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review , 2017, Patient preference and adherence.
[37] A. Hernández-Mijares,et al. Medication adherence and persistence in type 2 diabetes mellitus: perspectives of patients, physicians and pharmacists on the Spanish health care system , 2017, Patient preference and adherence.
[38] K. Khunti,et al. Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. , 2017, Primary care diabetes.
[39] Jun Ma,et al. Gender Differences in Weight-Related Attitudes and Behaviors Among Overweight and Obese Adults in the United States , 2016, American journal of men's health.
[40] W. Polonsky,et al. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors , 2016, Patient preference and adherence.
[41] Alan Martin,et al. Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. , 2016, Clinical therapeutics.
[42] S. Grandy,et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany , 2016, Diabetes, metabolic syndrome and obesity : targets and therapy.
[43] K. Boye,et al. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK , 2015, Patient preference and adherence.
[44] Marta Botella,et al. Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment , 2015, Patient preference and adherence.
[45] Z. Kadziola,et al. Increasing body mass index identifies Chinese patients with type 2 diabetes mellitus at risk of poor outcomes. , 2015, Journal of diabetes and its complications.
[46] A. Hauber,et al. A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus , 2015, Diabetes Therapy.
[47] Hiep Nguyen,et al. Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States , 2014, Advances in Therapy.
[48] J. Liberman,et al. Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study) , 2014, International journal of clinical practice.
[49] C. McAdam-Marx,et al. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. , 2014, Journal of managed care & specialty pharmacy.
[50] Tanjala S. Purnell,et al. Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review , 2014, Diabetes Care.
[51] A. Modi,et al. MEDICATION ADHERENCE TO ANTIDIABETIC THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS , 2014 .
[52] K. Fox,et al. Association of Weight Loss and Medication Adherence Among Adults With Type 2 Diabetes Mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)☆ , 2013, Current therapeutic research, clinical and experimental.
[53] F. Johnson,et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. , 2013, Diabetes & metabolism.
[54] A. Hauber,et al. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes , 2013, Patient preference and adherence.
[55] M. Brod,et al. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians , 2012, Current medical research and opinion.
[56] M. Brod,et al. Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses , 2012, Current medical research and opinion.
[57] Jeffrey K Aronson,et al. A new taxonomy for describing and defining adherence to medications. , 2012, British journal of clinical pharmacology.
[58] W. Polonsky,et al. Patient perspectives on once‐weekly medications for diabetes , 2011, Diabetes, obesity & metabolism.
[59] S. Bolge,et al. Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life. , 2010, Diabetes research and clinical practice.
[60] P. Mavros,et al. Patient‐reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain , 2009, Diabetes, obesity & metabolism.
[61] F. Johnson,et al. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose‐lowering agents , 2009, Diabetic medicine : a journal of the British Diabetic Association.
[62] Anuja Roy,et al. Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[63] A. Farmer,et al. Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[64] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[65] B. Chastek,et al. Impact of Treatment Complexity on Adherence and Glycemic Control : An Analysis of Oral Antidiabetic Agents , 2022 .